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In order to identify novel prognostic markers and actionable targets, we performed whole-exome/-transcriptome 
sequencing (WES/RNAseq) of relapsed childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) 
diagnosed in the Czech Republic. In patients with “B-other ALL” [BCP-ALL negative for ETV6-RUNX1, BCR-ABL1, TCF3-
PBX1, KMT2A rearrangement, hyperdiploidy (51-67 chromosomes) and hypodiploidy (< 44 chromosomes)], we found 
recurrent mutations of codons H1038 and Q1072 of the Zinc Finger E-Box Binding Homeobox 2 (ZEB2) gene. The 
ZEB2 gene is located on 2q22.3 and encodes a transcriptional repressor implicated in the pathogenesis of early T-cell 
ALL, possibly via deregulation of IL7R-JAK/STAT signaling
1, 2
. Codons H1038 and Q1072 are located in the C-terminal 
zinc finger coding-region (DNA binding region), however, impact of the mutations (ZEB2mut) on ZEB2 function is 
unknown. Although recurrence of ZEB2mut in BCP-ALL can be traced in a growing number of genomic studies3-6 their 
biological and clinical roles in BCP-ALL have not been described so far. 
 
In this study, we aimed to determine the frequency and clinical relevance of ZEB2mut in childhood B-other ALL. 
Using WES, RNAseq and amplicon sequencing of DNA or cDNA, we analyzed 231 and 36 Czech children with newly 
manifesting and relapsed B-other ALL, respectively (= “discovery cohorts”), consecutively diagnosed between 
November 2002 and December 2017 and treated according to several successive BFM-based protocols (see 
Supplementary Data). We detected ZEB2mut in 3.8% (9/231) of newly diagnosed B-other ALL. ZEB2mut was 
associated with significantly worse event-free survival and higher relapse (Figure 1A,B). In accord with the higher 
relapse rate, we found significant enrichment of ZEB2mut in relapse cohort (8/36, 29%; P=0.0005). Interestingly, 2 
out of total 9 relapses were isolated extramedullary, plus one combined. 
To validate these findings, we analyzed 626 and 102 children with newly diagnosed and relapsed B-other ALL 
diagnosed and treated in Germany (= “validation cohorts”). The frequency of ZEB2mut in the validation cohort of 
newly manifesting leukemias (enrolled into the AIEOP-BFM ALL 2000 and 2009 protocols) was 2.7% (17/626). While 
ZEB2mut was associated with a significantly higher relapse frequency in the patients enrolled into the AIEOP-BFM 
ALL 2000 study (Figure 1C,D), only 1/12 ZEB2mut patients enrolled in AIEOP-BFM ALL 2009 relapsed and two 
patients died without relapse. In the validation relapse cohort, ZEB2mut frequency was 4.9% (5/102), which was 
significantly lower compared to the discovery relapse cohort.  
The median time to relapse in all ZEB2mut-positive patients was 2.6 years from original diagnosis (range 0.9-5.3); the 
median follow-up time of those who remained in the first continuous complete remission was 6.1 years (range 1.7-
10.2). Among 24 ZEB2mut-positive patients treated on frontline protocols utilizing MRD-based risk stratification, 7, 
11 and 6 patients were stratified to standard, medium and high risk arms, respectively. 
Of the total 32 ZEB2mut patients identified within our study (for patients’ characteristics including distribution into 
cohorts, see Table 1 and Supplementary Table 1), the ZEB2mut was already detected at initial leukemia 
manifestation in 29. Among those, we found a male to female ratio 0.53, median age at diagnosis 8 years (10/29 
patients were ≥ 10 years old) and median initial white blood cell (WBC) count 8.2x10
9
/l (only 1 patient had ≥ 50x10
9
/l 
WBC). The H1038R, Q1072R and Q1072K mutations were found in 14, 13 and 2 patients, respectively. At the DNA 
level, the diagnostic variant allele frequencies (VAF) of ZEB2mut ranged from 2 to 79% (VAF ≤ 20% in 12/25 cases), 
pointing to a frequent subclonality (and thus an unlikely primary origin of ZEB2mut). VAFs of ZEB2mut alleles at the 
transcript level were mostly higher or comparable to those at the DNA level. Among 14 analyzed patients with paired 
diagnostic/relapse samples, ZEB2mut from diagnosis was preserved in 10 and lost in 1 patient, while in 3 patients 
ZEB2mut from relapse was undetectable at diagnosis and thus potentially newly gained.  
 
We utilized RNAseq to investigate the presence of subtype-defining genetic lesions, subtype-defining gene-
expression (GE) signatures4, 6-14 and other known genetic lesions in ZEB2mut-positive ALL.  
Out of 32 ZEB2mut-positive ALL cases, 6 were classified as DUX4-rearranged; the TCF3-HLF fusion and ZNF384 
rearrangement were found in one case each, while no subtype-defining lesion was detected by RNAseq in 24 cases. 
Out of those, iAMP21 was found by routine cytogenetic investigation in one case, while it was not consistently 
investigated in all patients. The ETV6-RUNX1-like and BCR-ABL1-like GE signatures were not detected in any patient 
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(Supplementary Figure 1). Thus, the majority of ZEB2mut-positive cases (23/32; 72%) did not belong to any 
established ALL subtype9. 
Variant and fusion analyses of RNAseq data revealed additional genes/pathways to be recurrently affected in 
ZEB2mut-positive cases (Table 1). Out of 28 ZEB2mut cases analyzed by RNAseq at initial leukemia manifestation, 7 
had the P2RY8-CRLF2 fusion. Of note, this fusion was significantly enriched in cases with the Q1072 mutations 
compared to those with the H1038 mutation (47% vs 0%, P=0.007). On the other hand, Ras pathway-activating 
mutations (mutations in NRAS, PTPN11 and FLT3) tended to be more frequent in cases with the H1038 mutation 
(38% vs 7%, P=0.07). Interestingly, in addition to genetic differences, patients with the two ZEB2mut types also 
differed by age. Patients with H1038 ZEB2mut were significantly older compared to those with Q1072 ZEB2mut 
(median age 12.4 versus 3.8 years; P=0.02). There was no significant difference in WBC count and a modest trend 
towards a higher frequency of males in H1038 compared to Q1072 ZEB2mut-positive patients (P=0.13).  
Other recurrently somatically affected genes were PAX5 (n=2) and TP53 (n=2). One patient harbored the IGH-CEBPA 
fusion, which was also found in an additional patient at relapse (unfortunately, in this patient we could not 
investigate its presence at initial manifestation). Of note, a recent transcriptomic study described a rare subgroup of 
BCP-ALL defined by GE signature, which was enriched for the ZEB2 H1038 mutation and the IGH-CEBPE fusion (likely 
functionally similar to IGH-CEBPA)3. However, unlike in our patients, these two genetic lesions did not co-occur in 
individual patients with the respective GE signature in the cited study. Last but not least, 3/32 patients harbored 
additional aberration of ZEB2 itself: a missense mutation affecting the second allele was found in one patient and 
out-of-frame fusions predicted to result in C-terminal truncation and modification of the ZEB2 protein in two 
patients (Table 1, Supplementary Figure 2); in both, the H1038 mutation was located on the rearranged allele. 
We further utilized RNAseq data to analyze the potential presence of GE signature associated with ZEB2mut. 
Unsupervised hierarchical clustering analyses revealed clusters that were enriched for either Q1072 or H1038 
ZEB2mut (Figure 2). None of these clusters involved all patients with the respective ZEB2mut, and, moreover, 
“H1038 ZEB2mut cluster” involved additional patients without ZEB2mut. Thus, ZEB2mut seems to impact GE 
signature, however less specifically and prominently compared to (at least some) subtype-defining genetic lesions 
(e.g. DUX4r, ETV6-RUNX1)
9, 15
. Whether the potential difference in GE signatures associated with H1038 versus 
Q1072 ZEB2mut derives truly from ZEB2mut type or it is (also) attributable to the differences in spectra of 
accompanying genetic lesions remains unclear.  
 
In summary, in this study we specified the frequency of H1038/Q1072 ZEB2mut in newly diagnosed and relapsed 
pediatric B-other ALL and their impact on outcome. While the discovery part of the study suggested ZEB2mut as a 
potential risk factor, and also the overall data from discovery plus validation cohorts confirm significant enrichment 
of ZEB2mut in relapse (26/857 at diagnosis vs 13/138 at relapse; P=0.0013), the original finding was only partly 
validated in independent cohorts. We may only speculate whether differences in treatment between AIEOP-BFM ALL 
2000 and 2009 protocols, potential selection bias in validation cohorts (that were non-consecutive and the validation 
relapse cohort did not include isolated extramedullary relapses) and/or small numbers of ZEB2mut-positive patients 
could contribute to these partially discordant findings. Although our study included more than 800 newly diagnosed 
B-other ALLs, the limited number of ZEB2mut-positive patients did not allow us to analyze the potential association 
of all biological and clinical features on relapse risk in deep detail. Nevertheless, we found no significant association 
between relapse occurrence and ZEB2mut type, ZEB2mut VAF, ALL subtype, concomitant genetic lesions, sex 
(although males tended to relapse more frequently than females - 70% vs 32% relapse incidence, P=0.06), age, WBC 
count or risk. With respect to the relatively low frequency of ZEB2mut, and potential dependence of its prognostic 
impact on additional genetic/clinical factors, further studies on well-characterized larger cohorts would be needed to 
further elucidate its clinical relevance, as well as biological studies addressing functional consequences of the 
mutations. 
We found genetic and demographic differences between patients with distinct ZEB2 mutations. There are currently 
no experimental data supporting assumption that distinct ZEB2mut types have the same (yet unknown) functional 
impact and biological consequences; moreover, the ZEB2 function can be further altered in patients with ZEB2 
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fusions. Thus, although we did not observe differences in relapse rate with respect to mutation type in our study, 
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835 F 7 6 MR B-other CCR 9,2 H1038R ZEB2-TEX41 (of) 
5 
n.an. 
206 M 6 8 SR B-other REL-BM 5,3 H1038R ZEB2-GTDC1 (of) 
5 
n.an. 
WB35 F 15 41 HR B-other CCR 4,3 H1038R TP53 P278L, NRAS Y64D n.an. 
WB23 F 9 3 HR B-other Died 0,7 H1038R PTPN11 G60V n.an. 
1768 M 1 3 SR B-other REL-BM 1,3 H1038R 
PAX5-PML, P2RY8-
CRLF2, CBFA2T3-
SLC7A5, JAK1 V658I 
PAX5-PML, P2RY8-
CRLF2, CBFA2T3-
SLC7A5, NT5C2 K25E 
H 46 F 12 4 HR B-other REL-BM 3,8 H1038R NRAS Q61K 
CSDE1-ST7L, KRAS 
A146V 
B 207 M 14 6 MR B-other 
REL-
BM+EM 
2,5 H1038R NRAS G12D _ 
KI63 F 20 22 MR B-other 
1 
REL-BM 0,9 H1038R n.an. IGH-CEBPA 
HV62 F 13 111 HR DUX4r 
1 
REL-BM 3,3 H1038R n.an. KRAS G12V 
GI9 F 9 15 SR B-other CCR 6,1 H1038R IGH-CEBPA n.an. 
U 131 M 16 9 MR B-other CCR 6,8 H1038R 
FLT3 D839G, L576R, 
N676K 
n.an. 
FB62 M 7 137 MR B-other REL-BM 2,7 H1038R _ _ 
865 M 17 4 MR B-other REL-BM 3,8 H1038R _ n.an. 
1883 M 12 7 HR B-other REL-BM 2,1 H1038R _ 
NT5C2 R238W, 
NT5C2 R367Q 
1098 F 14 20 MR DUX4r REL-BM 3,4 H1038R _ n.an. 
RG31 M 6 20 HR ZNF384r
 2 
CCR 6,0 H1038R _ n.an. 
961 M 12 3 HR iAMP21 REL-BM 2,5 Q1072R 
PAX5-BCAS4, KMT2D 
R5027*, SETD2 I2482fs 
n.an. 
E 46 F 3 3 SR B-other CCR 3,6 Q1072R PAX5 E105* n.an. 





B 65 F 4 4 SR B-other CCR 1,7 Q1072R 
P2RY8-CRLF2, JAK2 




B 80 F 3 8 MR B-other CCR 3,3 Q1072R 
P2RY8-CRLF2, CRLF2 
F232C, CRLF2 V244M 
n.an. 
HV70 F 2 41 MR B-other CCR 5,1 Q1072R P2RY8-CRLF2 n.an. 
KI16 F 4 35 SR B-other CCR 6,2 Q1072R P2RY8-CRLF2 n.an. 
1154 M 2 19 SR B-other CCR 6,0 Q1072R P2RY8-CRLF2 n.an. 
2058 M 3 5 SR B-other 
REL-
BM+CNS 
3,2 Q1072R P2RY8-CRLF2 SETD2 Y1666C 
RG51 F 9 8 HR TCF3/HLF Died 0,0 Q1072R NRAS G13D n.an. 
2134 F 4 10 MR DUX4r REL-EM 
4 
2,6 Q1072R IGH-MYC _ 
MA5 F 5 3 SR B-other REL-CNS 2,0 Q1072R ATG4D-PDE4A n.an. 
B 150 F 5 40 MR B-other REL-BM 1,8 Q1072R _ _ 
1114 M 17 16 MR DUX4r REL-EM 
3 
2,1 Q1072R _ n.an. 
KI15 F 9 6 MR DUX4r CCR 10,2 Q1072K _ n.an. 
1323 F 16 2 MR DUX4r CCR 9,0 Q1072K _ n.an. 
WBC - white blood cell count, SR/MR/HR - standard/medium/high risk, CCR - continuous complete remission, r-rearrangement, BM - bone 
marrow, EM - extramedullary, CNS - central nervous system, n.an. – not analyzed; DG – diagnosis, REL – relapse; of – out-of-frame. 
1 - Subtype assigned using RNAseq data from relapse; 2 - EP300-ZNF384; 3 - isolated testicular relapse; 4 - isolated relapse in uterus; 5 - 







Figure 1. Outcome analysis. Event-free survival and cumulative incidence of relapse at 5 years according to ZEB2mut 
status in patients with newly diagnosed B-other ALL from the discovery cohort (A, B) and those from the validation 
cohort who were treated on AIEOP-BFM ALL 2000 protocol (C,D). SE – standard error. 
 
Figure 2. Unsupervised hierarchical clustering. Unsupervised hierarchical clustering based on expression of 800 
most differentially expressed genes (across the whole sample set, n =156) was performed using ward.D method and 
Euclidean distance linkage. Figure shows resulting dendrogram. The sample set includes samples from the patients 
with ZEB2 mutations-positive B-other ALL from the present study and samples of the patients with B-other ALL, BCR-
ABL1-positive ALL and ETV6-RUNX1-positive ALL from our previous study
15
. The BCR-ABL1-positive and ETV6-RUNX1-
positive samples were included into the sample set to demonstrate the strength of co-clustering of ETV6-RUNX1-like 
and BCR-ABL1-like samples with their fusion-positive counterparts. Identification of the ETV6-RUNX1-like and BCR-
ABL1-like samples was done by supervised hierarchical clustering analyses (Supplementary Figure 1). Left-to right 
order of samples can be found in Supplementary Table 4. ZEB2 H1038 and Q1072 mutation clusters are highlighted 
by red and blue boxes, respectively. DG – diagnosis, REL – relapse, r-rearrangement, low – variant allele frequency at 
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PATIENTS, MATERIAL AND METHODS 
Patients 
The discovery cohort of this study included 231 and 36 children (age 1-18 years) with newly diagnosed and 
relapsed, respectively, B-cell precursor ALL negative for routinely screened aberrations (B-other ALL – ALL 
negative for hypodiploidy (≤ 44 chromosomes), high hyperdiploidy (51-67 chromosomes), ETV6-RUNX1, BCR-
ABL1, TCF3-PBX1 and KMT2A-involving gene fusions), who were diagnosed and treated in the Czech Republic 
between November 2002 and December 2017. The cohort of children with newly diagnosed B-other ALL 
represents 94% of all consecutively diagnosed children with this ALL subtype from the respective time period; 
in the remaining 6% of children no material was available for this study. These children were treated according 
to 3 consecutive protocols: ALLIC-BFM 2002 (ClinicalTrials.gov Identifier: NCT00764907), AIEOP-BFM ALL 2000 
(ClinicalTrials.gov Identifier: NCT00430118) and AIEOP-BFM ALL 2009 (ClinicalTrials.gov Identifier: 
NCT01117441); the last two protocols utilized minimal residual disease monitoring for risk stratification. The 
median follow up time of the children who remained in continuous complete remission was 5.2 years (range 1-
15 years). The cohort of children with relapsed B-other ALL represents 97% of all consecutive pediatric B-other 
ALL relapses from the respective time period, only a single child had no relapse material available for this study. 
Isolated extramedullary relapses were not excluded from the study. Thirty children are included in both cohorts 
(the cohort with newly diagnosed and the cohort of relapsed B-other ALL). 
Validation cohorts comprised 626 and 102 children (age 1-18 years; single patient was a 20 years-old adult) 
with newly diagnosed and relapsed ALL, respectively, from Germany. Patients were selected based on the 
negativity of routinely screened aberrations (hypodiploidy, hyperdiploidy, ETV6-RUNX1, BCR-ABL1, TCF3-PBX1 
and KMT2A-AFF1 gene fusions) and availability of material. The children with newly diagnosed ALL were 
treated on the AIEOP-BFM ALL 2000 (n=235) or AIEOP-BFM ALL 2009 (n=391) protocols. Only children with 
bone-marrow relapse or combined relapse with morphologically-detectable bone-marrow involvement were 
included in the validation relapse cohort. 
The study was approved by ethical review boards of participating institutions and the informed consent was 
obtained from the patient‘s parents in accordance with the Declaration of Helsinki. 
 
Biological samples processing 
Mononuclear cells (MNCs) were separated from diagnostic and remission bone marrow aspirates and 
peripheral blood samples by Ficoll-Paque (Pharmacia, Germany) gradient centrifugation. Total DNA and RNA 
were isolated from MNCs, and RNA was transcribed into cDNA as a part of the routine sample processing 
procedure. DNA isolated from samples collected in remission or from separated T lymphocytes was used as 
germline for whole-exome sequencing. 
 
Analysis of ZEB2 H1038 and Q1072 mutations 
The presence of mutations was analyzed at DNA and/or RNA levels using whole-exome sequencing (WES), 
whole-transcriptome sequencing (RNAseq) and amplicon sequencing of DNA or cDNA (AmpliSeq-DNA, 
AmpliSeq-cDNA). Supplementary Table 2 shows methods used for the discovery cohorts. The choice of the 
method was influenced by the availability of already existing WES/RNAseq data and/or of material. Part of the 
leukemia cases were analyzed by more methods; in all but one case, results obtained by different methods 
were concordant. In one case, ZEB2 Q1072R mutation with allele frequency 1.3% was detected by AmpliSeq-
cDNA, while it was not detected by WES, RNAseq and AmpliSeq-DNA. Validation cohorts were analyzed by 
AmpliSeq-DNA.  
 
Whole-exome and whole-transcriptome sequencing, subtype classification 
Sequencing and data analysis (variant calling, fusion detection, gene expression analysis and hierarchical 
clustering analysis) were performed as described previously (Zaliova et al., Haematologica 2019; doi: 
10.3324/haematol.2018.204974). 
In addition to routinely screened genetic aberrations, DUX4 rearrangement (r), ZNF384r, MEF2Dr, NUTM1r, 
TCF3-HLF, PAX5 P80R, IKZF1 N159Y and BCR-ABL1-like and ETV6-RUNX1-like gene expression signatures were 
considered as subtype-defining. 
Presence of gene expression signatures was analyzed by hierarchical clustering analyses (HCA).  For HCA, we 
pooled 30 and 10 samples of ZEB2mut-positive patients from initial manifestations and relapses, respectively, 
with the cohort of 110 patients with B-other ALL presented in our previous study (Zaliova et al., Haematologica 
2019; doi: 10.3324/haematol.2018.204974). To verify co-clustering of BCR-ABL1-like and ETV6-RUNX1-like 
subtypes with the respective genetic groups, we amended the cohort with 2 BCR-ABL1-positive and 9 ETV6-
RUNX1-positive ALL cases. 
 
Deep amplicon sequencing 
To perform bi-directional sequencing, part of the ZEB2 coding region (chr2:145147414-145147587; hg19) 
spanning over  codons H1038 and Q1072 (NM _014795) was amplified from DNA/cDNA in 2 separate single-
round PCR reactions using primer pairs listed in Supplementary Table 3. Resulting indexed libraries were 
sequenced on Ion Torrent PGM using 400bp chemistry according to the manufacturer’s instructions (Life 
Technologies, USA). Fastq files were processed from raw data and reads were mapped to hg19 using Torrent 
Suite software (Life Technologies). Variant calling was performed using Variant Caller plugin in Torrent Suite 
software (parameter settings: somatic variant frequency, low stringency). Mapped reads were visually 
inspected in IGV. 
Error rate at the positions of interest was repeatedly analyzed by sequencing of DNA from buffy coats collected 
from healthy individuals. It reached on average 0.09% and 0.06% (medians 0.05% and 0.07%) for codons H1038 
(chr2:145147549-145147551) and Q1072 (chr2: 145147447-145147449), respectively. The median sequencing 
depths were 10263 and 10966 for codons H1038 and Q1072, respectively (ranges 1230-52681 and 1328-53561 
reads). The mutation screening was performed using sensitivity of detection set to 1% mutated allele frequency 
(which corresponds to 2% cells with the mutation).  
Statistical analysis 
The Mann-Whitney U test was used to compare numerical parameters. The Fisher exact probability test was 
used to compare frequencies. The Kaplan-Meier method was used to estimate survival rates, differences were 
compared with the 2-sided log-rank test. Event-free survival (EFS) was defined as the time from diagnosis to 
the date of last follow-up in complete remission or to the first event. Events were resistance to therapy (non-
response), relapse, secondary neoplasm or death from any cause. Failure to achieve remission due to early 
death or non-response was considered as events at time zero. Patients lost to follow-up were censored at the 
time of their withdrawal. Cumulative incidence functions for competing events were estimated according to 








































































































































































































































































































865 D-DG M 17 4 
ALL IC-BFM 
2002 




F 14 20 
ALL IC-BFM 
2002 




M 12 7 
ALL-BFM 
2009 




M 17 16 
ALL IC-BFM 
2002 














F 4 10 
ALL-BFM 
2009 
MR DUX4r REL-EM 4 2,6 Q1072R 0% 1% Q1072R 28% 42% Yes IGH-MYC Yes _ 
835 D-DG F 7 6 
ALL IC-BFM 
2002 
MR B-other CCR 9,2 H1038R n.a. 32% n.ap. n.ap. n.ap. Yes ZEB2-TEX41 (of) 5 No n.ap. 
1323 D-DG F 16 2 
ALL-BFM 
2000 
MR DUX4r CCR 9,0 Q1072K n.a. 94% n.ap. n.ap. n.ap. Yes _ No n.ap. 
1154 D-DG M 2 19 
ALL-BFM 
2000 
SR B-other CCR 6,0 Q1072R 28% 39% n.ap. n.ap. n.ap. Yes P2RY8-CRLF2 No n.ap. 
206 D-REL M 6 8 
ALL-BFM 
95 




M 12 3 
ALL IC-BFM 
2002 
HR iAMP21 REL-BM 2,5 No n.ap. n.ap. Q1072R 9% 17% Yes 






M 1 3 
ALL-BFM 
2009 
SR B-other REL-BM 1,3 No n.ap. n.ap. H1038R 41% 43% Yes 
PAX5-PML, P2RY8-CRLF2, CBFA2T3-
SLC7A5, JAK1 V658I 
Yes 
PAX5-PML, P2RY8-CRLF2, 




M 7 137 
ALL BFM 
2000 




F 12 4 
ALL BFM 
2000 
HR B-other REL-BM 3,8 H1038R 28% 20% H1038R 37% 42% Yes NRAS Q61K Yes CSDE1-ST7L, KRAS A146V 
B 150 V-DG F 5 40 
ALL BFM 
2000 
MR B-other REL-BM 1,8 Q1072R 16% 19% No n.ap. n.ap. Yes _ Yes _ 
MA5 V-DG F 5 3 
ALL-BFM 
2009 
SR B-other REL-CNS 2,0 Q1072R 9% 23% n.a. n.a. n.a. Yes ATG4D-PDE4A No n.ap. 
U 131 V-DG M 16 9 
ALL BFM 
2000 
MR B-other CCR 6,8 H1038R 40% 41% n.ap. n.ap. n.ap. Yes FLT3 D839G, L576R, N676K No n.ap. 
GI9 V-DG F 9 15 
ALL-BFM 
2009 
SR B-other CCR 6,1 H1038R 38% 44% n.ap. n.ap. n.ap. Yes IGH-CEBPA No n.ap. 
RG31 V-DG M 6 20 
ALL-BFM 
2009 
HR ZNF384r 2 CCR 6,0 H1038R 22% 22% n.ap. n.ap. n.ap. Yes _ No n.ap. 
WB35 V-DG F 15 41 
ALL-BFM 
2009 
HR B-other CCR 4,3 H1038R 39% 40% n.ap. n.ap. n.ap. Yes TP53 P278L, NRAS Y64D No n.ap. 
WB23 V-DG F 9 3 
ALL-BFM 
2009 
HR B-other Died 0,7 H1038R 42% 44% n.ap. n.ap. n.ap. Yes PTPN11 G60V No n.ap. 
KI15 V-DG F 9 6 
ALL BFM 
2000 
MR DUX4r CCR 10,2 Q1072K 2% 1% n.ap. n.ap. n.ap. Yes _ No n.ap. 
B 65 V-DG F 4 4 
ALL-BFM 
2009 
SR B-other CCR 1,7 Q1072R 36% 40% n.ap. n.ap. n.ap. Yes 
P2RY8-CRLF2, JAK2 D873N, TP53 
E258G, ZEB2 A1035G 6 
No n.ap. 
B 80 V-DG F 3 8 
ALL-BFM 
2009 
MR B-other CCR 3,3 Q1072R 6% 10% n.ap. n.ap. n.ap. Yes 
P2RY8-CRLF2, CRLF2 F232C, CRLF2 
V244M 
No n.ap. 
E 46 V-DG F 3 3 
ALL-BFM 
2009 
SR B-other CCR 3,6 Q1072R 7% 30% n.ap. n.ap. n.ap. Yes PAX5 E105* No n.ap. 
HV70 V-DG F 2 41 
ALL-BFM 
2009 
MR B-other CCR 5,1 Q1072R 20% 39% n.ap. n.ap. n.ap. Yes P2RY8-CRLF2 No n.ap. 
KI16 V-DG F 4 35 
ALL-BFM 
2009 
SR B-other CCR 6,2 Q1072R 29% 44% n.ap. n.ap. n.ap. Yes P2RY8-CRLF2 No n.ap. 
S 29 V-DG F 3 30 
ALL-BFM 
2009 
MR B-other CCR 6,3 Q1072R 4% 7% n.ap. n.ap. n.ap. Yes 
P2RY8-CRLF2, PAX5 V319_P320fs, 
PAX5 A111T 
No n.ap. 
RG51 V-DG F 9 8 
ALL-BFM 
2009 
HR TCF3/HLF Died 0,0 Q1072R 8% 20% n.ap. n.ap. n.ap. Yes NRAS G13D No n.ap. 






2,5 H1038R 25% 88% H1038R 34% 94% Yes NRAS G12D Yes _ 
KI63 V-REL F 20 22 
ALL BFM 
2000 
MR B-other 1 REL-BM 0,9 H1038R 36% n.a. H1038R 22% 28% No n.ap. Yes IGH-CEBPA 
HV62 V-REL F 13 111 
ALL BFM 
2000 
HR DUX4r 1 REL-BM 3,3 No n.ap. n.ap. H1038R 38% 42% No n.ap. Yes KRAS G12V 
D-discovery, V - validation, DG - initial ALL manifestation, REL - ALL relapse, F -female, M - male, WBC - white blood cell count, SR/MR/HR - standard/medium/high risk, CCR - continuous complete remission, r-rearrangement, BM - bone marrow, EM - 
extramedullary, CNS - central nervous system, n.a. - not analyzed, n.ap. - not applicable, RNAseq - whole transcriptome sequencing, of -out-of-frame; 
1 - Subtype assigned using RNAseq data from relapse; 2 - EP300-ZNF384; 3 - isolated testicular relapse; 4 - isolated relapse in uterus; 5 - the rearranged allele carries H1038R mutation; 6 - affects second ZEB2 allele 
Supplementary Table 2. Methods used for ZEB2 mutation screening in discovery cohorts. 
 
 




















      1 1*   2   
       15     6 1 
        63     3 2 
        1     2   
       6 5       
        5         
        4 3       
         47         
              4 4 
         41     19 1 
         48         
 
  






Supplementary Table 3. Primers used to prepare libraries for amplicon sequencing. 
 
 








Dashes separate primer elements: P1 and A adapters, index, key, template specific primer (in bold italics) 
 




Supplementary Figure 1. Hierarchical clustering based on expression of genes defining ETV6-RUNX1-like and BCR-ABL1-like gene expression signature. 
Hierarchical clustering (ward.D method and Euclidean distance linkage) was performed using gene sets defining ETV6-RUNX1-like (A) and BCR-ABL1-like (B) subtypes described in Zaliova et al. (Haematologica 2019; doi: 
10.3324/haematol.2018.204974). Figure shows resulting dendrograms.  








Supplementary Figure 2. Scheme of the ZEB2 protein and its aberrations.  
Figure shows positions of codons H1038 and Q1072 in C-terminal Zinc fingers and point of junction to two identified fusion partners.  
Both TEX41 and GTDC1 genes are direct neighbors of ZEB2 (GTDC1 in centromeric and TEX41 in telomeric direction). The GTDC1 gene has the same orientation as ZEB2 and the fusion 
(transcript fusion point corresponds to the positions chr2:45147126 and chr2:144832796 at the genomic level) likely results from a deletion. The TEX41 gene has the opposite orientation 
and, thus, the fusion (transcript fusion point corresponds to the positions chr2:145147280 and chr2:145552498 at the genomic level) likely results from a more complex rearrangement.  
The ZEB2-TEX41 transcript is predicted to be translated into an aberrant protein where the last 103 amino acids of ZEB2 are replaced by 10 amino acids translated by readthrough into the 
TEX41 intron on the non-coding strand. Similarly, the last 51 ZEB2 amino acids are replaced by 4 amino acids resulting from readthrough into the GTDC1 intron in an aberrant protein 
potentially resulting from the ZEB2-GTDC1 fusion. 
 
 
 
